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Background/Aim: To analyse clinical response, overall (OS) and disease free survival (DFS) and
toxicity in patients with unresectable oesophageal cancer treated by concomitant chemo-
radiotherapy (CRT).
Materials and methods: Forty patients with stage IIa–IVa biopsy proven oesophageal carcinoma
were treated with CRT. All patients were studied with endoscopy and CT and judged unre-
sectable after multidisciplinary discussion. CRT consisted of 3 cycles of cisplatin 100 mg/m2
or carboplatin 300 mg/m2 on day 1 and 5-ﬂuorouracil 1000 mg/m2 as a continuous infusion
of  96 h associated with concurrent 3D-conformal RT. By using 15 MeV  X-rays, a total dose of
60–66  Gy was delivered with daily fractions of 1.8–2.0 Gy.
Results: Complete response (CR), partial response (PR) and no response (NR) were observed
in  50%, 20% and 20% of cases, respectively. Of the 20 patients with CR, 15 developed loco-
regional recurrent disease. OS and DFS rates at 3 and 5 years were 38%, 8%, 49% and
10%,  respectively. Total radiation dose ≥60 Gy improved loco-regional control and complete
response (CR vs. PR + NR; p = 0.004) inﬂuenced both DFS and loco-regional control. Grade
3  gastrointestinal and haematological acute toxicity occurred in 3/40 patients (7.5%). One
patient developed grade 4 renal failure. Late toxicity was reported in 2/40 patients (5.0%),
consisting of grade 3 radiation pneumonitis.Conclusions: Concomitant CRT for unresectable oesophageal cancer can result in an accept-
able  loco-regional control with limited toxicity. Response after treatment and total radiation
dose  inﬂuenced the outcome.
©  2012 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z.o.o. All∗ Corresponding author at: Radiotherapy, University Hospital “Maggiore
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Table 1 – Main patient and tumor characteristics.
Characteristics Patient number %
Gender
Male 31 77.5
Female 9 22.5
Performance status (ECOG)
0 4 10
1 25 62.5
2 9 22.5
Tumor location
Upper third 12 30
Middle third 18 45
Lower third 3 7.5
Multiple sites 7 17.5
Clinical stage
IIA 15 37.5reports of practical oncology and 
.  Background
esophageal cancer is a quite uncommon tumour entity
ccounting approximately for 1% of all malignancies and for
% of gastrointestinal tumours.1 The incidence of oesophageal
ancer has risen in recent years in Western countries mainly
n relation to an increased incidence of the adenocarcinoma
f the lower oesophagus.2 It is in principle a treatable tumour
ut rarely curable. Clinical presentation is often with advanced
nd unresectable disease, occurring the diagnosis in early
tage (<T1b) in less than 10% of cases.3 Three-year survival
ates of patients with oesophageal cancer undergoing surgery
lone in clinical trials range from 6% to 36%,1 whereas 5-year
urvival rates of patients treated by radiotherapy alone are
eported to be 0–10%.4
Combined modality therapy with chemotherapy and radio-
herapy has become a standard treatment for oesophageal
ancer over the last decade. International guidelines includ-
ng the National Comprehensive Cancer Network5 consider
hemo-radiation to be an appropriate treatment option for
tage II and III when unﬁt for surgery and for stage IVa in
elected cases.
. Aim
he aim of the present study is to analyse clinical response,
verall survival (OS), disease free survival (DFS) and toxicity
n patients with unresectable oesophageal cancer treated by
oncomitant chemo-radiotherapy.
.  Materials  and  methods
etween January 1994 and June 2010, 106 patients with
esophageal cancer were referred to the Department of Radio-
herapy of the University Hospital “Maggiore della Carità” in
ovara, Italy. Of these 106 patients, 20 were treated in pre-
r postoperative setting, 46 received only palliative radiother-
py and 40 were treated by concomitant chemo-radiotherapy
ith a radical intent. These 40 patients were included in the
resent retrospective study that was approved by the local
eview committee. Thirty one patients (77.5%) were male and 9
emale (22.5%) with median age of 66 years (range 52–79 years).
erformance status assessed by the ECOG scale6 ranged from
 to 2 (median 1). At biopsy, 38/40 patients (95%) had squa-
ous cell carcinoma and 2/40 (5%) adenocarcinoma. Other
umour characteristics are reported in Table 1. All cases were
tudied with endoscopy and computed tomography (CT)-scan
nd 17/40 (42.5%) also with positron emission tomography
PET)/CT imaging. The lymph nodes status was assessed by
T and, in case of nodal enlargement >1 cm,  by eco-endoscopy
nd/or PET/CT. All cases were judged to be candidates for rad-
cal chemo-radiotherapy after multidisciplinary discussion.
hemotherapy consisted of 3 cycles of cisplatin 100 mg/m2 or
arboplatin 300 mg/m2 on day 1 and 5-ﬂuorouracil 1000 mg/m2s a continuous infusion of 96 h. Three dimension conformal
adiotherapy was given concomitantly to chemotherapy by
sing 6–15 MeV  X-rays starting during the ﬁrst cycle. Gross
umour volume (GTV) was outlined on CT images in 23/40IIB 1 2.5
III 21 52.5
IV 3 7.5
cases (57.5%) and on PET/CT fused images in 17/40 cases
(42.5%). For delineation on PET/CT images, a ﬁxed thresh-
old value of 40% of the maximum uptake in the lesion was
adopted. Prescribed total dose was 46–50 Gy, possibly fol-
lowed by a boost of up to 60–66 Gy with daily fractionation of
1.8–2.0 Gy/die. The highest dose levels were prescribed in the
case of larger tumour volume and no severe toxicity during the
ﬁrst part of the treatment. Four–eight weeks after the end of
chemo-radiotherapy, all patients underwent repeat endoscopy
and CT-scan to assess tumour response. The 17 cases studied
with PET/CT at diagnosis were re-scanned with PET/CT 3–4
weeks after treatment completion to asses metabolic tumour
response. Follow-up was performed every 6 months during
the ﬁrst 3 years and then yearly by clinical assessment, blood
test, endoscopy and CT-scan. Acute toxicity was scored by the
National Cancer Institute-Common Toxicity Criteria Version
4.0 based on data recorded in the patients’ charts and late tox-
icity was assessed by the Radiation Therapy Oncology Group
(RTOG)/European Organization for Research and Treatment of
Cancer (EORTC) late radiation morbidity scoring scheme.7,8
3.1.  Statistical  analysis
Actuarial OS and DFS were calculated by the Kaplan Meier
method. Univariate analysis was performed by the Log Rank
test for OS, DFS and loco-regional control (LRC) considering
the following parameters: age, clinical stage, N-stage, grad-
ing, response to treatment, and radiation dose. A p-value < 0.05
was considered to be statistically signiﬁcant. The correlation
between total dose (≥60 Gy vs. <60 Gy) and clinical response
(CR vs. PR + NR) was analysed by the 2 test.
4.  Results
Of the 40 patients included in the present study, 36 (90%)
completed the chemo-radiotherapy program. Two patients
stopped chemotherapy after the ﬁrst cycle for renal toxicity
grade G3, but completed radiotherapy reaching the total dose
of 60 Gy and the other two patients stopped chemotherapy
after the second cycle: one at the radiation dose of 21.6 Gy for
disease progression and the other one at the dose of 40 Gy
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Table 2 – Univariate analysis (log-rank test).
N. of patients Overall survival Disease free survival Loco-regional control
Age (y)
<65 21
p  = 0.61 p = 0.87 p = 0.80≥65 19
Stage
Stage IIA–IIB 16
p  = 0.28 p = 0.66 p = 0.65Stage III 21
Stage IV 3
N category
N0 24
p  = 0.83 p = 0.31 p = 0.30
N1 16
Histological grading
G < 3 22
p  = 0.30 p = 0.38 p = 0.29
G = 3 18
Response to treatment
Complete response 20
p  = 0.11 p  = 0.0006 p  = 0.0003Partial response 8
No response 8
Complete response 20
p  = 0.32 p = 0.0001 p = 0.0001
Partial response + no response 16
treated by surgery may be explained by the fact that the
lower third location, where such histology typically arises,
is more  often approached by surgical resection. Seven cases
– Acute (CTCAE Version 4.0) and late toxicity (RTOG
scale).
Acute toxicity Grade
1
Grade
2
Grade
3
Grade
4
Hematological
Anemia 4 4 2 –
Leukopenia 2 3 – –
Thrombocytopenia 8 2 – –
Gastrointestinal
Nausea – 4 2 –
Vomiting – 4 2 –
Hematemesis 1 – – –
Dysphagia-Esophagitis – 5 1 –
Renal failure – – 1 1
Mucositis – 1 2 –Dose (Gy)
<60 Gy 26
p  = 0.53 ≥60 Gy 14
for cachexia. The dose actually delivered in the whole series
ranged from 21.6 Gy to 66 Gy (median 54 Gy).
After chemo-radiotherapy, 20/40 patients (50%) showed a
complete response (CR), 8/40 (20%), partial response (PR), and
8/40 (20%) no response (NR). The 2 test showed a trend for a
possible statistical correlation between total dose and clinical
response (p = 0.067). Four patients died before response assess-
ment, three for disease progression and one for myocardial
infarction. Of the 20 patients with CR, 15 (75%) developed loco-
regional recurrence after 5–36 months (median 12 months) as
ﬁrst relapse of disease.
Follow-up time ranged from 3 to 60 months with a median
of 21 months. Median survival time was 22.5 months. OS rates
at 2, 3 and 5 years were 52%, 38% and 8%, respectively. DFS
rates at 2, 3 and 5 years were 54%, 49% and 10%, respec-
tively (Fig. 1). By univariate analysis, the clinical response after
treatment inﬂuenced DFS: the 2-year DFS rate was 100% for
patients with CR vs. 24% for patients with PR + NR (p = 0.0001).
Clinical response and total radiation dose <60 Gy or ≥60 Gy
improved LRC (p = 0.02) (Table 2) (Figs. 2–4).
Metastases were detected in 12/40 patients (30%): in 4 cases
to the lymph nodes and in 8 cases to other distant sites includ-
ing the lung, bone, liver and brain.
Acute toxicity, mainly gastrointestinal and haematologi-
cal, occurred with grade 1–2 in 21/40 patients (52.5%) and with
grade 3 in 3/40 patients (7.5%). Only one patient experienced
grade 4 toxicity due to a renal failure after cisplatin admin-
istration. Late toxicity was reported in 2/40 patients (5.0%),
consisting in both cases of grade 3 radiation pneumonitis
(Table 3).
5.  DiscussionWhen oesophageal cancer presents with unresectable dis-
ease, the general consensus is to treat it using a combined
approach with chemotherapy and radiotherapy since thep = 0.06 p = 0.02
beneﬁt of deﬁnitive chemo-radiation over radiation alone has
been well documented.9 The recommendation from litera-
ture studies, based on small but randomized experience, is to
treat both squamous and adenocarcinoma cell histology in a
similar way by using ﬂuoropyrimidine plus another cytotoxic
agent.3,10–12
Our series does not substantially differ from other litera-
ture series in terms of gender and age distribution, showing
a prevalence of males and a median age of 66 years. Most
cases arose from the upper and middle oesophageal third and
presented with squamous cell carcinoma histology, whereas
only 5% of cases were diagnosed with adenocarcinoma. The
relatively low percentage of adenocarcinoma in our series
compared with the tumour presentation from other seriesErythema – 2 – –
Late toxicity
Angina – 1 – –
Radiation pneumonitis – – 2 –
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17.5%) presented with multiple locations in relation to a
ulticentre origin of the tumour. This aspect was reported
lso by Morita et al. who found an association of the loss of
ragile histidine triad gene expression with alcohol induced
arcinogenesis and multicentre tumour presentation.13
dvanced clinical stage distribution of our series ranging
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Fig. 2 – Node status and dise disease free survival (DFS).
from IIa to IVa was relatively less favourable compared
with other studies that used a similar chemo-radiotherapy
approach.9,14,15Seventeen of our patients were studied also by PET/CT
imaging that was used both for staging and for treatment
planning purposes. In the recent years, PET/CT has been
70605040
N 0
P = 0.049
e  (m onths)
ase free survival (DFS).
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t anFig. 3 – Response to treatmen
implemented for the identiﬁcation and delineation of target
volume as well as for the response assessment after treat-
ment completion in several tumour locations but only a few
of the recent literature studies have described the use of
PET/CT in oesophageal cancer. Interestingly, FDG-PET per-
formed after induction chemotherapy or before concomitant
chemo-radiation may be useful in predicting a ﬁnal tumour
response16 and FDG-PET after chemo-radiation may predict
patients’ prognosis.17 In this regard, we are still following our
patients who  underwent PET/CT to understand whether this
functional information can correlate with clinical outcome.
Treatment schedule was very similar over time for all
our patients. Chemotherapy regimen was substantially the
same, including cisplatin or carboplatin, mainly in relation to
the patients’ renal function. Nowadays, other new drugs like
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Fig. 4 – Dose and locod disease free survival (DFS).
docetaxel, epirubicin, irinotecan and capecitabine, tested in
various literature studies for preoperative or radical chemo-
radiotherapy, failed to show a substantial improvement of
prognosis of the disease.3 The addition of target therapy to
chemo-radiotherapy schemes seems to be a new promising
approach that has been preliminarily tested in controlled
clinical trails.18 Radiotherapy was conducted with a similar
3D-conformal technical approach. The changes over time have
been in the more  detailed dosimetry documentation with
dose-volume histograms since 1999 and the implementation
of PET/CT imaging for assistance in target identiﬁcation and
delineation since 2005. The prescribed total dose was higher
(60–66 Gy) than that reported in most literature studies and
recommended in the NCCN guidelines.5 As a matter of fact,
a total dose of 45–50 Gy was prescribed to the target volume
40 50 60 70
Dose ≥ 60 Gy 
P = 0.02 
 time (months)
-regional control.
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nd, in case of large tumour volume, whenever possible, a
oost dose was applied of up to 60–66 Gy in the attempt to
ncrease local tumour control. In this regard, the majority of
ur patients (26/40, 65%) were able to effectively reach such
 high dose level. In other literature series, high dose-rate
rachytherapy was used to either intensify the dose or palliate
ymptoms.19,20
The overall response rate after chemo-radiation, assessed
y endoscopy and CT, was 70% with 50% of CR. Other authors
eport response rates ranging from 38% to 96% with aver-
ge CR rates of 60% and up to 96%. Interestingly, 11–79%
mean 32%) of pathological responses were reported after
reoperative chemo-radiotherapy when radiation is usually
iven to a total dose of about 40–50 Gy and the response
ates seem to be higher for treatment regimens that include
 concomitant administration of radiation and platinum
ompounds.14,15,21–24
The median survival time (22.5 months) and the OS and
FS rates at 2, 3 and 5 years of 52%, 38% and 8% and of 54%,
9% and 10%, respectively, observed in our series, are basically
n the range of the recent literature data, despite a relatively
nfavourable patient selection that included mainly stage III
nd also stage IVa disease.15,21,23–26 The most frequent pat-
ern of relapse was loco-regional, accounting for 75% of cases
ho obtained CR after treatment. Such percentage is similar
o that observed in some literature studies9,14 but higher than
hat reported in others.15,23,24 This difference may be related
o the different stage distribution. Univariate analysis showed
hat clinical response after treatment correlated with DFS and
linical response and total radiation dose ≥60 Gy correlated
ith higher loco-regional control rate. Similarly, other litera-
ure studies showed that CR after treatment completion may
nﬂuence favourably the outcome.19 In our series, the histo-
ogical grading <3 and the dose ≥60 Gy showed only a trend
or better DFS, whereas some literature studies observed a
tatistical signiﬁcance of these parameters.25
Acute toxicity was mainly of grade 1–2 (52%) and only
n 4 cases (10%) was it of higher grade. Grade 3 late effects
onsisting of radiation pneumonitis occurred only in 2 cases
5%). Similar or higher toxicity rates were reported by other
uthors.14,15,21
The main limitations of our study are the retrospective
esign and the relatively small number of patients not allow-
ng to perform a multivariate analysis. On the other hand, the
reatment characteristics were substantially homogeneous
ver time and the median follow-up was adequate to observe
nd report long-term outcome.
.  Conclusions
his observational study showed that concomitant chemo-
adiotherapy for unresectable oesophageal cancer is feasible
nd can result in an acceptable rate of local control with
imited toxicity in a clinical series treated outside prospec-
ive controlled clinical trials. Loco-regional recurrence was
he most frequent pattern of relapse and OS rates at 2, 3
nd 5 years were similar to those of other literature series.
he clinical response after treatment inﬂuenced DFS and the
1therapy 1 7 ( 2 0 1 2 ) 226–232 231
clinical response, and the use of high radiation doses improved
loco-regional control.
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